The Top 5 Biosimilars Articles for the Week of May 11

May 15, 2020

Here are the top 5 biosimilars articles for the week of May 11, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of May 11, 2020.

Number 5: With 1 biosimilar launch and expanded indications for another biosimilar so far this year, Teva Pharmaceutical Industries reported higher biosimilar revenues in the first quarter of 2020.

Number 4: A systematic review of nonmedical-switching studies of patients with inflammatory bowel disease , also known as IBD, has detailed the knowledge gaps and study limitations responsible for this hesitation by gastroenterologists.

Number 3: Eye health business Bausch + Lomb said it has entered into an agreement to commercialize in the United States and Canada Xlucane,a ranibizumab biosimilar candidate currently under development.

Number 2: The FDA’s new focus on coronavirus disease 2019 (COVID-19) and the quarantines imposed on much of the developed world have pushed digital and remote marketing of pharmaceutical products into high gear, according to Jamie Peck, managing director of iON.

Number 1: The Federal Trade Commission was deeply divided over whether the AbbVie-Allergan $63 billion merger plan would allow for a sufficiently competitive marketplace.

To read all of these articles and more, visit centerforbiosimilars.com.